Biomarin Pharmaceutical (BMRN) Other Non-Current Liabilities (2009 - 2026)

Biomarin Pharmaceutical has disclosed Other Non-Current Liabilities across 18 years of filings, most recently posting $155.5 million for Q1 2026.

• Quarterly Other Non-Current Liabilities rose 19.89% year-over-year to $155.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $155.5 million (up 19.89% YoY) and the FY2025 annual result came in at $150.8 million, up 17.07% from the prior year.
• Other Non-Current Liabilities advanced to $155.5 million in Q1 2026, from $150.8 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $163.1 million in Q3 2025 and troughed at $92.4 million in Q1 2023.
• A 5-year average of $123.5 million and a median of $119.9 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Biggest YoY gain for Other Non-Current Liabilities was 209.69% in 2022; the steepest drop was 1.68% in 2022.
• Tracing BMRN's Other Non-Current Liabilities over 5 years: stood at $100.0 million in 2022, then rose by 19.92% to $119.9 million in 2023, then climbed by 7.41% to $128.8 million in 2024, then advanced by 17.07% to $150.8 million in 2025, then advanced by 3.09% to $155.5 million in 2026.
• Business Quant data shows BMRN's Other Non-Current Liabilities at $155.5 million in Q1 2026, $150.8 million in Q4 2025, and $163.1 million in Q3 2025.